AMCAL NICOTINE LOZENGES 4mg nicotine (as nicotine polacrilex) lozenge blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

nicotine polacrilex, Quantity: 26.66 mg (Equivalent: nicotine, Qty 4 mg)

Available from:

Orion Laboratories Pty Ltd T/A Perrigo Australia

INN (International Name):

Nicotine polacrilex

Pharmaceutical form:

Tablet, uncoated

Composition:

Excipient Ingredients: sodium alginate; potassium bicarbonate; magnesium stearate; sodium carbonate; mannitol; xanthan gum; aspartame; Flavour

Administration route:

Buccal

Units in package:

144, 96, 168, 120, 108, 156, 132, 72, 36

Prescription type:

Not Scheduled after consideration by Committee

Therapeutic indications:

Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.

Product summary:

Visual Identification: Cream/white embossed biconvex round tablet with a peppermint odour. Embossed with ?L873? on one face; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2013-08-15